Who are PCV chemotherapy alone's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Eloxatin, Doxorubicin hydrochloride liposome, Folfox-7, DSP, PUVA (8MOP + UVA) + IFN, Cisplatin / Carboplatin，Gemcitabine，Cindilimab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pcv-chemotherapy-alone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

PCV chemotherapy alone — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PCV chemotherapy alone (PCV chemotherapy alone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: chemotherapy. Area: Oncology.

phase 3 chemotherapy Oncology Small molecule Live · refreshed every 30 min

Target snapshot

PCV chemotherapy alone (PCV chemotherapy alone) — Assistance Publique - Hôpitaux de Paris. PCV chemotherapy involves the combination of three chemotherapy drugs: methotrexate, cyclophosphamide, and vincristine, which work together to kill rapidly dividing cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
PCV chemotherapy alone TARGET	PCV chemotherapy alone	Assistance Publique - Hôpitaux de Paris	phase 3	chemotherapy
Eloxatin	Oxaliplatin	Yakult Honsha	marketed	Platinum-based chemotherapy agent	DNA	2002-01-01
Doxorubicin hydrochloride liposome	Doxorubicin hydrochloride liposome	Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.	marketed	Anthracycline chemotherapy agent (liposomal formulation)	DNA topoisomerase II
Folfox-7	folfox-7	Pfizer	marketed	chemotherapy	DNA replication machinery
DSP	DSP	Taiwan Liposome Company	marketed	Liposomal anthracycline chemotherapy	Topoisomerase II
PUVA (8MOP + UVA) + IFN	PUVA (8MOP + UVA) + IFN	Madrilenian Group of Cutaneous Lymphomas	marketed	Photochemotherapy + cytokine combination
Cisplatin / Carboplatin，Gemcitabine，Cindilimab	Cisplatin / Carboplatin，Gemcitabine，Cindilimab	People's Hospital of Quzhou	marketed	Combination chemotherapy with immune checkpoint inhibitor	DNA (platinum agents, gemcitabine); PD-L1 (cindilimab)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (chemotherapy class)

Pfizer · 3 drugs in this class
Chengdu New Radiomedicine Technology Co. LTD. · 1 drug in this class
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · 1 drug in this class
Chinese Society of Lung Cancer · 1 drug in this class
Hutchmed · 1 drug in this class
Prof. Massimo Aglietta · 1 drug in this class
Sanofi · 1 drug in this class
Sun Yat-sen University · 1 drug in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Swiss Cancer Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PCV chemotherapy alone — Competitive Intelligence Brief. https://druglandscape.com/ci/pcv-chemotherapy-alone. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing